25 results
Thumbnail

D1.281 - Development of a Peanut-Specific Human Mast Cell Assay for Screening Probiotics and other Nutritional Components with Anti-Allergic Potential

Thumbnail

D1.284 - Eosinophilic Esophagitis Before and After Milk Oral Immunotherapy in Children with Food Allergy: A Case Series Including the Eosinophil-to-Lymphocyte Ratio

Thumbnail

D1.278 - Dragon fruit Allergy: A Case of Cross-Reactivity and Dietary Risks

Thumbnail

D1.279 - Oral Immune Tolerance Induction Therapy with IFN-gamma in children with rice allergy

Thumbnail

D1.280 - Microbiome Signatures Associated with Food Allergy Resolution in Children

Thumbnail

D1.283 - Endolysosomal degradation of major peanut allergens revealed distinct degradation kinetics and T cell epitope regions

Thumbnail

D1.285 - Novel food supplement containing a combination of postbiotics and plant-derived compounds regulates epithelial barrier integrity and immune response in human enterocytes

Thumbnail

D1.286 - Allergenic Protein Profiling in a Patient with Long-standing Nut-Induced Anaphylaxis

Thumbnail

D1.287 - Polysensitization to Seed Storage Proteins, LTPs and Profilin in a Patient With Anaphylaxis After Consumption of Pesto Sauce

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis

Thumbnail

D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)

Thumbnail

D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)

Thumbnail

D1.441 - A Bispecific Antibody Targeting IL13 and IL31 for the Treatment of Inflammatory Skin Diseases

Thumbnail

D1.444 - Dual Blockade of IL22 and IL23 with a bispecific antibody: A Promising Strategy for the Treatment of Psoriasis and Other Autoimmune Skin Disorders